Skip to main content
. 2022 Apr 15;72(2):345–359. doi: 10.1136/gutjnl-2021-325564

Figure 6.

Figure 6

Loxl2 is necessary for PDAC intravasation. (A–B) Mean lung tumour weight ±SD in (A) wild type (+/+, ID32) KPC and Het KPC (KPC; Loxl2 +/-, ID86) cells (blue) and KO KPC (KPC; Loxl2 -/-, ID90 and ID98) cells (red) or (B) wild type (+/+, ID15 and ID29) KPC cells (blue) and KPCL2KI (KPC; R26L2+/KI, ID63 and KPC; R26L2KI/KI, ID4) cells (green) at 4 weeks post injection in NOD-SCID immunodeficient mice (left) (ns, not significant; unpaired Student’s t-test). Representative images of extracted lungs (top, right) and H&E images (bottom, right). (C) Experimental set-up for in vivo orthotopic tumour establishment in NOD-SCID immunodeficient mice with H2b-mCherry-labelled KPCL2KO (KPC; Loxl2 -/-) cells or EGFP+KPCL2KI (KPC; R26L2KI/KI) cells, alone or at a 1:1 ratio (groups 1, 3 and 2, respectively). (D) Mean tumour weight ±SD, 4 weeks post orthotopic injection, for each group (n=5 mice per group) (left). Representative images of PDAC tumours (right). (E–G) Mean number (no.) of mCherry-positive (red) or EGFP-positive (green) cells in (E) tumour homogenates, (F) blood or (G) liver homogenates, in indicated groups (*p<0.05, **p<0.01, ***p<0.001; ns, not significant; unpaired Student’s t-test). Het, heterozygous; KI, knock-in; KO, knockout; Loxl2, lysyl oxidase-like protein 2; PDAC, pancreatic ductal adenocarcinoma; wt, wild type.